RT @EuRefNetwork: ERKNet expert Gema Ariceta reviews optimal duration of #Eculizumab therapy in #aHUS in a recent @Ped_Neph editorial https…
RT @EuRefNetwork: ERKNet expert Gema Ariceta reviews optimal duration of #Eculizumab therapy in #aHUS in a recent @Ped_Neph editorial https…
always helping #aHUS #patients #SHUa #shua24sept #objetivoCERO #salvarVIDAS @vallhebron
ERKNet expert Gema Ariceta reviews optimal duration of #Eculizumab therapy in #aHUS in a recent @Ped_Neph editorial https://t.co/hCp93Ax2oV
RT @pedsnephrology: One of the best summaries ( and guidance) on Eculizumab in #aHUS ==> Optimal duration of treatment with eculizumab in a…
Optimal duration of treatment with eculizumab in atypical hemolytic uremic syndrome (#aHUS)—a question to be addressed in a scientific way https://t.co/BtGkuLmEIl @Ped_Neph
RT @ASPNeph: Optimal duration of treatment with eculizumab in atypical hemolytic uremic syndrome (#aHUS)—a question to be addressed in a sc…
Optimal duration of treatment with eculizumab in atypical hemolytic uremic syndrome (#aHUS)—a question to be addressed in a scientific way https://t.co/SHE9gOwaOS @Ped_Neph
RT @Ped_Neph: 🆕 Editorial Optimal duration of treatment with eculizumab in atypical hemolytic uremic syndrome (aHUS)—a question to be add…
RT @pedsnephrology: One of the best summaries ( and guidance) on Eculizumab in #aHUS ==> Optimal duration of treatment with eculizumab in a…
RT @aHUSAllianceAct: Conclusion builds re optimal #eculizumab #Tx : “Originally approved for long-life treatment, clinical experience from…
RT @pedsnephrology: One of the best summaries ( and guidance) on Eculizumab in #aHUS ==> Optimal duration of treatment with eculizumab in a…
RT @pedsnephrology: One of the best summaries ( and guidance) on Eculizumab in #aHUS ==> Optimal duration of treatment with eculizumab in a…
One of the best summaries ( and guidance) on Eculizumab in #aHUS ==> Optimal duration of treatment with eculizumab in atypical hemolytic uremic syndrome (#aHUS )—a question to be addressed in a scientific way @Ped_Neph https://t.co/GwjzKYLkjB
RT aHUSAllianceAct Conclusion builds re optimal #eculizumab #Tx : “Originally approved for long-life treatment, clinical experience from highly expert centers support moving from a fixed treatment schedule to a personalized dosing, at least in selected p…
Conclusion builds re optimal #eculizumab #Tx : “Originally approved for long-life treatment, clinical experience from highly expert centers support moving from a fixed treatment schedule to a personalized dosing, at least in selected patients.” https://t.c
RT @Ped_Neph: 🆕 Editorial Optimal duration of treatment with eculizumab in atypical hemolytic uremic syndrome (aHUS)—a question to be add…
🆕 Editorial Optimal duration of treatment with eculizumab in atypical hemolytic uremic syndrome (aHUS)—a question to be addressed in a scientific way https://t.co/k4JaWA43cM Shareable link: https://t.co/qqaxkhNCED @vallhebron #eculizumab #aHUS https://